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Anti-metastatic mechanism of Tian-Xian Liquid (TXL) 
and its bioactive fractions in human colorectal cancer 
cells and xenograft models
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Sciences, Faculty of Medicine, The Chinese University of Hong Kong
Colorectal carcinoma is the second most prevalent cancer with an up-rising trend in Hong Kong (Hong Kong Cancer 
Registry). Traditional Chinese medicine acts as a complementary alternative for tumour therapy with minimal side-
effects and traumatic injuries. Tian-Xian Liquid (TXL), one of the well-known natural medicinal herbal formulations, has 
been commercially used as an anticancer dietary supplement for a decade without known adverse effects. This study 
aimed to investigate the anti-metastatic property of TXL and its bioactive fractions [butanol fraction (BU), ethyl-acetate 
fraction (EA) and aqueous fraction (WA)] at molecular level on human colorectal cancer in vitro (HT-29 cancer cells) and 
in vivo (nude mice xenografts). For the cell model, TXL and its bioactive fractions have similar anti-proliferative effects by 
MTT assay. At 4-hour-incubation, IC50 values were obtained at 1% (V/V) TXL, 1.25% (V/V) BU, 5% (V/V) EA and 0.3125% 
(V/V) WA. At IC50, TXL and its bioactive fractions significantly reduced the MMP2 and MMP7 expressions at mRNA level 
by real-time PCR. At protein level, TXL, BU and EA correspondingly down-regulated MMP2 (active form) and MMP7 
protein from 24 to 48 hours; TXL and BU also down-regulated VEGF protein expression; however, no such effect was 
found in WA-treated cells. Further, only TXL, EA and WA effectively inhibited the cell migration at 48 hours incubation by 
woundhealing assay. For the xenografts models, MMP2 and MMP7 mRNA expressions were reduced by TXL-, BU- and 
EA-treated xenografts; however no effects on MMP2 protein expression in all drug-treated xenografts. The VEGF protein 
expression was significantly down-regulated in TXL- and WA-treated xenografts. Further, TXL, BU and WA effectively 
inhibited the tumor growth without altering the body weight of the xenografts. In summary, the Chinese medicinal 
formulation, TXL, demonstrated the most effective anti-metastatic ability on human colorectal cancer in vitro and in vivo.
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Trans-differentiation of breast cancer by GATA3 reduces 
primary growth and metastasis
Isabel Chu, Aleksandra Michalowski and Jeffrey Green
Laboratory of Cancer Biology and Genetics, National Cancer Institute, Maryland, USA
Low-grade breast cancer is associated with increased differentiation and reduced metastases, suggesting that 
reprogramming tumor cells to a more differentiated state could improve outcome. Previous differentiation strategies 
for breast cancer have failed. Utilizing a novel differentiation therapy approach, we have reprogrammed aggressive, 
basal, triple-negative Breast Cancer (BrCa) (generally with poor prognosis) towards a less aggressive phenotype by 
manipulating expression of the key mammary luminal differentiation transcription factor, GATA3. GATA3 is essential 
for programming undifferentiated mammary cells into a luminal subtype while myoepithelial/basal cells fail to express 
GATA3. Significantly, GATA3 expression is highly correlated with the luminal, more differentiated BrCa phenotype. We 
hypothesized that ectopic expression of GATA3 in metastatic, basal BrCa cell lines will reprogram them to a more 
differentiated, less metastatic phenotype. Over-expressing GATA3 in human basaltype MDA-MB-231 (231-GATA3) BrCa 
cells induced significant morphological changes in 2- and 3-D cultures compared to control cells (231-Emty). 231-Empty 
cells maintained a spindle, elongated morphology, while 231-GATA3 cells became rounded and larger. In 3-D Cultrex, 
231-GATA3 cells appeared smaller, more organized, and rounded compared to 231-Empty cells. Microarray profiling 
of 231- GATA3 vs. 231-Empty cells revealed gene expression changes associated with increased adhesion, reduced 
extracellular matrix remodeling factors and reduced metastasis. Western blot confirmed re-expression of E-cadherin 
and reduction of fibronectin in 231-GATA3 cells, indicative of a more luminal phenotype. The gene most downregulated 
by GATA3 was Lysyl Oxidase (LOX) and confirmed by qPCR. LOX has been shown to be critical for metastatic progression 
through matrix remodeling. Knock down of GATA3 in the GATA3 positive BT474 cell line increased LOX expression. 
Retrospective analysis of microarray profiles of BrCa cells revealed an association of LOX with the basal subtype and a 
statistical inverse association between LOX and GATA3. SCID mice injected with 231-GATA3 cells by tail vein showed 
significantly fewer metastatic lesions in the lung compared to control cells (p<0.05). Importantly, restoration of LOX 
in 231-GATA3 cells by lentiviral transduction reversed the reduced metastatic phenotype. This demonstrates that 
expression of GATA3 reprogrammed a poorly differentiated basal cell towards a less metastatic phenotype and the 
GATA3 dependent LOX down-regulation is responsible for the reduced observed metastasis. These findings suggest that 
transcription factor-induced differentiation pathways may be potentially novel therapeutic molecular targets to inhibit 
metastatic disease progression in combination with standard therapeutic treatments.
